This podcast features expert discussion on the emerging role of type 2 (T2) inflammation in chronic obstructive pulmonary disease (COPD) and the implications for payer and provider decision-making. Faculty review key pathophysiologic mechanisms and biomarkers—particularly eosinophil counts—that identify patients most likely to benefit from targeted biologic therapies. The conversation also explores updated GOLD guideline recommendations, strategies to optimize formulary access, the impact of T2 inflammation on long-term outcomes, and opportunities to reduce hospitalizations and oral steroid use. Health plan professionals will gain insights into aligning policies with evolving clinical evidence and enhancing care coordination to improve outcomes.

This activity is certified for CME/CNE/CPE credit. To participate and earn 

credit, visit us at https://www.impactedu.net/type2-inflammation-copd-management/.